Impact of mepolizumab in severe asthma with nasal polyps

Background: Severe asthma is frequently associated with chronic rhinosinusitis with nasal polyps (CRSwNP), contributing to poor asthma control. In literature, the use of mepolizumab in patients with severe asthma and CRSwNP has shown to reduce exacerbations and improve quality of life. Aim: To compare the impact of mepolizumab in severe asthma patients with and without CRSwNP regarding several outcomes. Materials and methods: Multicenter retrospective study of severe asthma patients under mepolizumab in 2020. Results: 22 severe asthma patients were included and both groups - with and without CRwNP - were homogeneous concerning sex, age, BMI and smoking habits. Discussion: Although there were no differences in outcomes between the two groups it seems that patients with CRSwNP have a greater need for short-term use of OCS followed by a greater reduction after mepolizumab. In patients with CRSwNP mepolizumab had an important role in improving quality of life, evidence by a reduction in the total score of ACT and SNOT-22